ATARA BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-16
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-03-31 was $12.00M, a 263.64% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-12-31 was $3.50M, a 12.90% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-09-30 was $4.50M, a 28.57% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-06-30 was $4.90M, a 53.13% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $2.90M, a 67.78% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $9.00M, a 47.06% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $17.00M, a 26.72% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $23.20M, a 12.78% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.90M 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $9.00M 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $17.00M 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $23.20M 10-K · filed 2024-03-28 | |||
| 2021-12-31 | $26.60M 10-K · filed 2023-02-08 | |||
| 2020-12-31 | $29.40M 10-K · filed 2023-02-08 | |||
| 2019-12-31 | $31.60M 10-K · filed 2022-02-28 | |||
| 2019-03-31 | $12.00M 10-Q · filed 2019-05-09 | $15.50M derived: sum of 2 quarters · filed 2021-03-01 | $20.00M derived: sum of 3 quarters · filed 2021-03-01 | $24.90M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $8.00M derived: sum of 2 quarters · filed 2021-03-01 | $12.90M derived: sum of 3 quarters · filed 2021-03-01 | $16.20M 10-K · filed 2021-03-01 |
| 2018-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $9.40M derived: sum of 2 quarters · filed 2018-11-06 | $12.70M 10-Q · filed 2018-11-06 | $15.80M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $8.20M 10-Q · filed 2018-08-01 | $11.30M derived: sum of 3 quarters · filed 2020-02-27 | $14.80M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $3.30M 10-Q · filed 2019-05-09 | $6.40M derived: sum of 2 quarters · filed 2020-02-27 | $9.90M derived: sum of 3 quarters · filed 2020-02-27 | $13.10M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $6.60M derived: sum of 2 quarters · filed 2020-02-27 | $9.80M derived: sum of 3 quarters · filed 2020-02-27 | $14.00M 10-K · filed 2020-02-27 |
| 2017-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $6.70M derived: sum of 2 quarters · filed 2018-11-06 | $10.90M 10-Q · filed 2018-11-06 | $14.50M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $7.40M 10-Q · filed 2018-08-01 | $11.00M derived: sum of 3 quarters · filed 2019-02-26 | $15.10M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $4.20M 10-Q · filed 2018-05-08 | $7.80M derived: sum of 2 quarters · filed 2019-02-26 | $11.90M derived: sum of 3 quarters · filed 2019-02-26 | $15.50M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $7.70M derived: sum of 2 quarters · filed 2019-02-26 | $11.30M derived: sum of 3 quarters · filed 2019-02-26 | $14.00M 10-K · filed 2019-02-26 |
| 2016-09-30 | $4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $7.70M derived: sum of 2 quarters · filed 2017-11-09 | $10.40M 10-Q · filed 2017-11-09 | $11.40M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $6.30M 10-Q · filed 2017-08-07 | $7.30M derived: sum of 3 quarters · filed 2018-02-27 | $8.10M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $2.70M 10-Q · filed 2017-05-04 | $3.70M derived: sum of 2 quarters · filed 2018-02-27 | $4.50M derived: sum of 3 quarters · filed 2018-02-27 | $5.20M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.80M derived: sum of 2 quarters · filed 2018-02-27 | $2.50M derived: sum of 3 quarters · filed 2018-02-27 | $2.90M 10-K · filed 2018-02-27 |
| 2015-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.50M derived: sum of 2 quarters · filed 2016-11-04 | $1.90M 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $1.10M 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $400.00K 10-Q · filed 2016-05-06 | |||
| 2014-12-31 | $100.00K 10-K · filed 2017-03-09 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |